Two Sigma Investments LP Cuts Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Two Sigma Investments LP decreased its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 33.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,100 shares of the company’s stock after selling 2,100 shares during the period. Two Sigma Investments LP owned about 0.10% of Invesco Biotechnology & Genome ETF worth $273,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PBE. Citadel Advisors LLC bought a new position in Invesco Biotechnology & Genome ETF in the fourth quarter valued at $569,000. Commonwealth Equity Services LLC lifted its holdings in shares of Invesco Biotechnology & Genome ETF by 16.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,002 shares of the company’s stock valued at $1,730,000 after purchasing an additional 3,764 shares during the last quarter. Bank of America Corp DE raised its holdings in Invesco Biotechnology & Genome ETF by 3.2% in the 4th quarter. Bank of America Corp DE now owns 68,973 shares of the company’s stock worth $4,589,000 after acquiring an additional 2,116 shares during the last quarter. Jones Financial Companies Lllp raised its stake in Invesco Biotechnology & Genome ETF by 52.9% during the 4th quarter. Jones Financial Companies Lllp now owns 2,315 shares of the company’s stock valued at $154,000 after buying an additional 801 shares during the last quarter. Finally, LPL Financial LLC grew its position in shares of Invesco Biotechnology & Genome ETF by 1.7% during the 4th quarter. LPL Financial LLC now owns 92,105 shares of the company’s stock valued at $6,128,000 after acquiring an additional 1,503 shares during the period.

Invesco Biotechnology & Genome ETF Price Performance

NYSEARCA:PBE opened at $64.63 on Thursday. Invesco Biotechnology & Genome ETF has a one year low of $54.52 and a one year high of $72.84. The firm has a market capitalization of $228.79 million, a price-to-earnings ratio of 20.39 and a beta of 0.79. The business has a fifty day moving average price of $61.24 and a 200-day moving average price of $65.35.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.